Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | MTOR | P42345 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25279197 | 0.87 | PIK3CA (0.34) | PIK3CAMTORPIK3CGNAMPTPIK3CD | |
| SCHEMBL25733488 | 0.85 | AR (0.34) | PIK3CAMTORPIK3CGHTT | |
| SCHEMBL31730968 | 0.85 | AR (0.34) | PIK3CAMTORPIK3CGHTT | |
| SCHEMBL31730879 | 0.85 | GPR119 (0.43) | GPR119PIK3CAMTORPIK3CGATR | |
| SCHEMBL25733559 | 0.85 | GPR119 (0.43) | GPR119PIK3CAMTORPIK3CGATR | |
| SCHEMBL25229561 | 0.83 | PIK3CA (0.34) | PIK3CAMTORPIK3CGHTT | |
| SCHEMBL31730923 | 0.81 | PIK3CD (0.45) | GPR119PIK3CAMTORPIK3CGATR | |
| SCHEMBL25733410 | 0.81 | PIK3CD (0.45) | GPR119PIK3CAMTORPIK3CGATR | |
| SCHEMBL30308860 | 0.80 | GPR119 (0.45) | GPR119PIK3CAMTORPIK3CGATR | |
| SCHEMBL25720155 | 0.80 | GPR119 (0.45) | GPR119PIK3CAMTORPIK3CGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | GPR119 1751/4885PIK3CA 132/4885MTOR 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.